2 Stocks That Could Soar This Year
In the volatile biotech industry, companies can see their shares soar over relatively short periods on strong clinical progress for exciting pipeline candidates.
That's precisely what could happen to (NASDAQ: EXEL) and Summit Therapeutics (NASDAQ: SMMT) this year. And the even better news is that there are reasons to consider holding onto these drugmakers' shares even beyond the next 12 months. Let's find out more.
Image source: Getty Images.
Source Fool.com
Exelixis Inc. Stock
€35.10
-6.650%
With 32 Buy predictions and 1 Sell predictions Exelixis Inc. is one of the favorites of our community.
With a target price of 41 € there is a slightly positive potential of 16.81% for Exelixis Inc. compared to the current price of 35.1 €.
